RichardDCarvajalMD

PubMed

• 1 citations
  A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
  Lin, C., Garralda, E., Schöffski, P., Hong, D., Siu, L., Martin, M., Maur, M., Hui, R., Soo, R., Chiu, J., Zhang, T., Ma, B., Kyi, C., Tan, D., Cassier, P., Sarantopou...> ;Oncoimmunology. 2024 Jan 1
• Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond.
  Lanyi Nora Chen, Richard D Carvajal> ;Annals of Translational Medicine. 2023 Aug 30
• 7 citations
  Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma.
  Sungsoo Kim, Richard Carvajal, Minah Kim, Hee Won Yang> ;Cell Reports. 2023 Jun 27
• 6 citations
  Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors HarboringAmplification.
  Elias, A., Siqing Fu, Shuyang Yao, Yuan Yuan, Rebecca A Previs, Anthony D Elias, Richard D Carvajal, Thomas J George, Ying Yuan, Lihou Yu, Shannon N Westin, Yan Xing, ...> ;Journal of Clinical Oncology. 2023 Mar 20
• 1 citations
  Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
  Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, William H Sharfman, Julie R Brahmer, Donald P Lawrence, Michael B Atkins, Joh...> ;Journal of Clinical Oncology. 2023 Feb 10
• 13 citations
  A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.
  S Piperno-Neumann, M S Carlino, V Boni, D Loirat, F M Speetjens, J J Park, E Calvo, R D Carvajal, M Nyakas, J Gonzalez-Maffe, X Zhu, M D Shirley, T Ramkumar, A Fesseha...> ;British Journal of Cancer. 2023 Apr 1
• 30 citations
  Advances in the clinical management of uveal melanoma.
  Richard D Carvajal, Joseph J Sacco, Martine J Jager, David J Eschelman, Roger Olofsson Bagge, J William Harbour, Nicholas D Chieng, Sapna P Patel, Anthony M Joshua, So...> ;Nature Reviews. Clinical Oncology. 2023 Feb 1
• 7 citations
  Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens.
  Yiping Wang, Joy Linyue Fan, Johannes C Melms, Amit Dipak Amin, Yohanna Georgis, Irving Barrera, Patricia Ho, Somnath Tagore, Gabriel Abril-Rodríguez, Siyu He, Yinuo J...> ;Nature Genetics. 2023 Jan 1
• Editorial: Non-cutaneous melanoma: new therapeutic insights.
  Rossi, E., Carvajal, R.> ;Frontiers in Oncology. 2023 Jan 1
• 3 citations
  SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response.
  Kranthi Kiran Kishore Tanagala, Joshua Morin-Baxter, Richard Carvajal, Maryum Cheema, Sunil Dubey, Hiroshi Nakagawa, Angela Yoon, Yi-Shing L Cheng, Alison Taylor, Jeff...> ;Journal for Immunotherapy of Cancer. 2022 Dec 1
• 39 citations
  Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
  Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, Jessica C Hassel, Alexandra Ikeguchi, Leonel Hernandez-Aya, Paul Nathan, Omid Hamid, Josep M Piulats, Matt...> ;Nature Medicine. 2022 Nov 1
• 4 citations
  A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastat...
  Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, Mark Agulnik, Mohammed M Milhem, Suzanne George, Robin L Jones, Bartosz Chmielowski, Brian A Van Tine, Hussein Tawbi,...> ;European Journal of Cancer. 2022 Nov 1
• 16 citations
  First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.
  Todd Bauer, Byong Chul Cho, Rebecca Heist, Lyudmila Bazhenova, Theresa Werner, Sanjay Goel, Dong-Wan Kim, Douglas Adkins, Richard D Carvajal, Ajjai Alva, Keith Eaton, ...> ;Investigational New Drugs. 2022 Oct 1
• 9 citations
  Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
  Lanyi Nora Chen, Richard D Carvajal> ;Expert Review of Anticancer Therapy. 2022 Oct 1
• Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
  Ascierto, P., Agarwala, S., Blank, C., Caracò, C., Carvajal, R., Ernstoff, M., Ferrone, S., Fox, B., Gajewski, T., Garbe, C., Grob, J., Hamid, O., Krogsgaard, M., Lo, ...> ;Journal of Translational Medicine. 2022 Sep 4
• 5 citations
  Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
  Seungyeon Jung, Emma Armstrong, Alexander Z Wei, Fei Ye, Aaron Lee, Matteo S Carlino, Ryan J Sullivan, Richard D Carvajal, Alexander N Shoushtari, Douglas B Johnson> ;British Journal of Cancer. 2022 Nov 1
• 6 citations
  Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
  Alex W Liu, Alexander Z Wei, Ashray B Maniar, Richard D Carvajal> ;Expert Opinion on Biological Therapy. 2022 Aug 1
• 46 citations
  Dissecting the treatment-naive ecosystem of human melanoma brain metastasis.
  Jana Biermann, Johannes C Melms, Amit Dipak Amin, Yiping Wang, Lindsay A Caprio, Alcida Karz, Somnath Tagore, Irving Barrera, Miguel A Ibarra-Arellano, Massimo Andreat...> ;Cell. 2022 Jul 7
• 17 citations
  Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
  F Dimitriou, K Namikawa, I L M Reijers, E I Buchbinder, J A Soon, A Zaremba, P Teterycz, M J Mooradian, E Armstrong, Y Nakamura, M G Vitale, L E Tran, X Bai, C Allayou...> ;Annals of Oncology. 2022 Sep 1
• 2 citations
  Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
  Jonathan W Goldman, Sarina A Piha-Paul, Brendan Curti, Katrina S Pedersen, Todd M Bauer, Stefanie L Groenland, Richard D Carvajal, Vaishali Chhaya, Gray Kirby, Kelly M...> ;Clinical Cancer Research. 2022 Sep 1
• 25 citations
  Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
  Richard D Carvajal, Paul Nathan, Joseph J Sacco, Marlana Orloff, Leonel F Hernandez-Aya, Jessica Yang, Jason J Luke, Marcus O Butler, Sarah Stanhope, Laura Collins, Ch...> ;Journal of Clinical Oncology. 2022 Jun 10
• 11 citations
  Uveal Melanoma Exosomes Induce a Prometastatic Microenvironment through Macrophage Migration Inhibitory Factor.
  Grazia Ambrosini, Alex J Rai, Richard D Carvajal, Gary K Schwartz> ;Molecular Cancer Research. 2022 Apr 1
• 10 citations
  New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma.
  Alexander Z Wei, Ashray B Maniar, Richard D Carvajal> ;Cancer Gene Therapy. 2022 Dec 1
• 35 citations
  Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis.
  Laurent Dercle, Binsheng Zhao, Mithat Gönen, Chaya S Moskowitz, Ahmed Firas, Volkan Beylergil, Dana E Connors, Hao Yang, Lin Lu, Tito Fojo, Richard Carvajal, Sanja Kar...> ;JAMA Oncology. 2022 Mar 1
• 63 citations
  Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
  Patrick Schöffski, Daniel S W Tan, Miguel Martín, María Ochoa-de-Olza, John Sarantopoulos, Richard D Carvajal, Chrisann Kyi, Taito Esaki, Amy Prawira, Wallace Akerley,...> ;Journal for Immunotherapy of Cancer. 2022 Feb 1
• Join now to see all

Journal Articles

• Clinical Trial Designs for Rare Diseases: Studies Developed and Discussed by the International Rare Cancers Initiative  
  Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher..., Eur J Cancer, 1/1/2015
• GNAQ and GNA11 Mutations in Uveal Melanoma  
  Shoushtari AN, Carvajal RD, Melanoma Res, 1/1/2014
• Selecting Patients for KIT Inhibition in Melanoma  
  Carvajal R, Hamid O, Antonescu C, Methods Mol Biol., 1/1/2014
• Treatments for Noncutaneous Melanoma  
  Khalil DN, Carvajal RD, Hematol Oncol Clin North Am, 1/1/2014
• Ipilimumab for Patients with Advanced Mucosal Melanoma  
  Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwa..., Oncologist, 1/1/2013
• Surveillance Options for Patients with Uveal Melanoma following Definitive Management  
  Francis JH, Patel SP, Gombos DS, Carvajal RD, Am Soc Clin Oncol Educ Book, 1/1/2013
• What Does the Future Hold for Uveal Melanoma, a Historically Untreatable Disease?  
  Shoushtari AN, Carvajal RD, Clin Invest, 1/1/2013
• Selumetinib Induced "Dropped Head Syndrome: Report of Three Cases  
  Chen X, Schwartz GK, DeAngelis LM, Kaley T, Carvajal RD, Neurology, 1/30/2012
• Ipilimumab Induced Colitis on FDG PET/CT  
  Lyall A, Vargas A, Carvajal RD, Ulaner G, Clin Nucl Med, 1/1/2012
• A New Era for the Management of Metastatic Melanoma  
  Koneru M, Carvajal RD, of Dermatology, 1/1/2012
• Therapeutic Implications of KIT in Melanoma  
  Postow M, Carvajal RD, The Cancer Journal: The Journal of Principles & Practice of Oncology, 1/1/2012
• Ipilimumab for Metastatic Melanoma  
  Ozao-Choy J, Carvajal RD, Hamid O, Drugs of Today, 1/1/2012
• GSK-1120212, a MEK1/MEK2 Inhibitor for the Potential Oral Treatment of Cancer  
  Postow M, Carvajal RD, Thomson Reuters' Drug Profiles, 1/1/2012
• Characterization of Computed Tomography Scan Abnormalities in Patients with Biopsy-proven Hepatic Metastases from Uveal Melanoma  
  Patel M, Winston CB, Marr BP, Carvajal RD, Schwartz GK, Wolchok J, Busam K, Abramson DH, Archives of ophthalmology, 1/1/2011
• Treatment of Metastatic Melanoma: A New World Opens  
  Smyth, EC, Carvajal RD, The Skin Cancer Foundation Journal, 1/1/2011
• Targeting KIT for the Treatment of Advanced Melanoma  
  Carvajal, RD, The Melanoma Letter, 1/1/2011
• Radiotherapy after Surgical Resection for Head and Neck Mucosal Melanoma  
  Wu AJ, Gomez J, Zhung JE, Chan K, Gomez DR, Wolden SL, Zelefsky MJ, Wolchok JD, Carvajal RD, Chapman PB, Wong RJ, Shaha AR, Kraus DH, Shah JP, Lee NY, American Journal of Clinical Oncology, 1/1/2010
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral Cyclin-dependent Kinase Inhibitor AZD5438 When Administered at Intermittent and Continuous Dosi...  
  Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JH, Sha..., Ann Oncol, 1/1/2010
• Possible Role of Edotecarin, a Novel Topoisomerase I Inhibitor, in Therapy-related Myelodysplastic Syndrome  
  Carvajal R, Ilson DH, Noy A, Leukemia and Lymphoma, 1/1/2007
• Aurora Kinases: New Targets for Cancer Therapy  
  Carvajal R, Tse A, Schwartz GK, Clinical Cancer Research, 1/1/2006
• Ewing's Sarcoma and Primitive Neuroectodermal Family of Tumors  
  Carvajal R, Meyers P, Hematology/Oncology Clinics of North America, 1/1/2005
• The Cyclin-dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Phase I Clinical Trial  
  Luke JJ, D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, de Stanchina E, Musi E, Singer S, Schwartz GK, Clin Cancer Res, 1/28/2012
• Atypical Melanocytic Proliferations and New Primary Melanomas in Advanced Melanoma Patients Undergoing Selective BRAF Inhibition  
  Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, Egberts F, Hauschild A, Kashani-Sabet M, Goldinger SM, Dummer R, Long G, McArthur G, Scherag A, ..., J Clin Onc, 1/21/2012
• Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer  
  Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake..., N Engl J Med, 1/2./2012
• Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) In Patients with BRAFV600E/K-mutated Melanoma  
  Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T, Lacouture ME, Panageas KS, Wolchok JD, Carvajal RD, Schwartz GK, Rosen N, Chapman PB, Clin Cancer Res, 1/15/2013
• Join now to see all

Books/Book Chapters

• Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies 
  Chapter: Surveillance for Early Detection of Metastatic Ocular Melanoma following Definitive Local Therapy 
  Page 193.0 - 209.0Francis JH, Kivela T, Carvajal RDEditors: Murray TG, Boldt HC.Future Medicine, London, UK2014
• Textbook of Uncommon Cancers 
  Chapter: Unusual Melanomas 
  Page 685.0 - 690.0Hamid O, Carvajal RD, Morton DL, Faries MEditors: Raghavan D, Blanke CD, Johnson DH, Moots PL, Reaman GH, Rose PG, Sekeres MA.John Wiley & Sons, Inc, Hoboken, NJEdition 4th,2012
• Dx/Rx: Melanoma. Massachusetts 
  Carvajal RDJones and Bartlett Publishers2010
• Cancer Management: A Multidisciplinary Approach 
  Brady MS, Kaushal A, Ko C, Carvajal RDEditors: Haller DG, Wagman LD, Camphausen KA, Hoskins WJ.PRR IncEdition 12th,2013
• Join now to see all

Abstracts/Posters

• Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM)
  Carvajal RD, Annual Meeting of the American Society of Clinical Oncology Melanoma Oral Abstract Session, Chicago, Illinois, 1/1/2013
• Rationale, Study Design and Accrual Status of a Randomized Phase II Study of AZD6244 (MEK Inhibitor) vs Temozolomide in Advanced Uveal Melanoma
  Carvajal RD, Macula, New York, New York, 1/1/2012
• A Randomized Phase II Trial of Temozolomide versus AZD6244 in Patients with Metastatic Uveal Melanoma
  Carvajal RD, Cancer Therapy Evaluation Program Early Drug Development Meeting, Bethesda, Maryland, 1/1/2011
• Rationale, Study Design and Accrual Status of a Randomized Phase II Study of AZD6244 versus Temozolomide in Advanced Uveal Melanoma
  Carvajal RD, International Society of Ocular Oncology Biennial Meeting, Buenos Aires, Argentina, 1/1/2011
• A Phase II Study of Imatinib Mesylate (IM) For Patients with Advanced Melanoma Harboring Somatic Alterations of KIT
  Carvajal RD, Annual Meeting of the American Society of Clinical Oncology Clinical Science Symposium, Chicago, Illinois, 1/1/2009
• Join now to see all

Lectures

• Targeted Therapy for Melanoma 
  Columbia University Medical Center, New York, New York - 1/1/2015
• Uveal Melanoma as a Model for Targeted Therapy 
  Columbia University Medical Center, New York, New York - 1/1/2015
• Building Bridges: A Fast(er) Track to the Bedside 
  Columbia University Medical Center, New York, New York - 1/1/2015
• Vision for Experimental Therapeutics at CUMC 
  Columbia University Medical Center, New York, New York - 1/1/2015
• Targeted Therapy for Uveal Melanoma: Biology, Clinical Trials & Challenges 
  Silver Spring, MD - 1/1/2014
• Ocular & Mucosal Melanoma: New Directions 
  Rutgers Cancer Institute of New Jersey, New Brunswick, NJ - 1/1/2014
• Harnessing the Immune System for the Treatment of Melanoma 
  Culver City, California - 1/1/2014
• The Early Drug Development Program at MSKCC 
  Memorial Sloan Kettering Cancer Center, 2014; Memorial Hospital, New York, New York, 2014 - 1/1/2014
• How to Run a Phase I Clinic: The Early Drug Development Program at MSKCC 
  New York, New York - 1/1/2014
• The New Science of Targeted Therapy: FDA's Viewpoint on Companion Diagnostics for Targeted Studies and Marker Trials 
  New York, New York - 1/1/2014
• Rare Melanomas as a Model for Targeted Therapy 
  Memorial Sloan Kettering Cancer Center, New York, New York - 1/1/2014
• Pathway Targeted Therapy for Melanoma 
  New York, New York - 1/1/2014
• GNAQ/11 Mutations in Melanoma: Opportunities for Drug Development 
  New York, New York - 1/1/2014
• Targeted Agents & Immunotherapy for Melanoma 
  Providence, Rhode Island - 1/1/2014
• Challenges for the Development of Therapy Trials 
  Philadelphia, Pennsylvania - 1/1/2013
• Targeted Therapy: Ongoing Trials in Uveal Melanoma 
  Philadelphia, Pennsylvania - 1/1/2013
• Rationale for Systemic Therapy of Uveal Melanoma and Review of Current and Future Clinical Trials for Uveal Melanoma 
  Chicago, Illinois - 1/1/2013
• Melanoma 101 
  Memorial Sloan Kettering Cancer Center - 1/1/2013
• Melanoma 
  Memorial Sloan Kettering Cancer Center, 2014; Memorial Hospital, New York, New York, 2013 - 1/1/2013
• Gq/11 Mutations in Melanoma: Implications for Drug Development 
  Memorial Sloan Kettering Cancer Center, New York, New York - 1/1/2013
• Systemic Therapy for Uveal Melanoma 
  Philadelphia, Pennsylvania - 1/1/2013
• Florida Society of Dermatology & Dermatologic Surgery (FSDDS) 2012 Annual Meeting 
  Florida Society of Dermatology & Dermatologic Surgery, Orlando, Florida - 5/25/2012
• Response Assessment for Cancer Immunotherapeutics: Immune-Related Response Criteria 
  Boston, Massachusetts - 1/1/2012
• Ipilimumab: Promise and Pitfalls 
  Boston, Massachusetts - 1/1/2012
• International Collaborative Efforts in Drug Development for Uveal Melanoma 
  Ft. Lauderdale, Florida - 1/1/2012
• Join now to see all

Other

• Emerging Treatments for Metastatic Melanoma 
  Teleconference, CancerCare
  1/1/2013
• Opportunities and Challenges in the Development of Adjuvant Therapies for Uveal Melanoma 
  Webinar, CureOM
  1/1/2012
• Systemic Treatment Options for Uveal Melanoma 
  Webinar, Melanoma International Foundation
  1/1/2011
• Soft Tissue Sarcoma Staging. Medscape Reference 
  Carvajal, RD
  http://emedicine.medscape.com/article/2006584-overview
  1/20/2011
• Soft Tissue Treatment Protocols. Medscape Reference 
  Carvajal, RD
  http://emedicine.medscape.com/article/2007168-overview
  1/1./2012
• Uveal and Conjunctival Melanomas 
  Gragoudas ES, Lane AM, Shih AH, Carvajal RD, UpToDate
  1/3./2013
• Mucosal melanoma 
  Carvajal RD, Ariyan C, Hamid O
  http://www.uptodate.com/contents/mucosal-melanoma
  UpToDate, Wolters Kluwer Health - 2012-06-11
• Join now to see all